NSW and Victoria report no new local Covid cases as hotel quarantine worker in Melbourne diagnosed with UK variant. Follow all the latest news and updates, live

• WHO says it is ‘too early’ to dismiss AstraZeneca vaccine
• Victoria Covid hotspots; NSW Covid hotspots
• Victoria reported no new cases in past 24 hours
• South Africa suspends AstraZeneca vaccinations

2.55am GMT

On the vaccine distribution in Australia, Paul Kelly says it is still on track for the first injections to be happening before the end of February, but will not put an exact timeline on it.

The aim will be to get 20 million doses of the Pfizer vaccine before the end of this year, in weekly deliveries. Kelly said the AstraZeneca and Novovax vaccines will also be used if and when they are approved by the TGA:

We don’t want a lot of vaccines sitting out in warehouses, so we will be looking to roll out particularly for those priority populations that people will know about now, as soon as we can. But then will be going back to the same population, those people, to give them a second dose. That is really important.

We will await the TGA advice in relation to AstraZeneca but some of the information that has been coming up in the last few weeks is that it may actually be a longer interval for that second dose.”

2.50am GMT

Australia’s chief medical officer, Prof Paul Kelly, is also moving to reassure people about the effectiveness of the AstraZeneca Covid-19 vaccine.

He said it was still in the process of being approved by the Therapeutics Goods Administration, and talked down claims it was less effective in treating the South African variant of the virus.

I just want to make a very clear statement about people taking small amounts of information quickly, without looking at it carefully. And making conclusions. At the moment, I can absolutely say, and this may change in future, and we will be nimble in the way we look at that information, and putting that into our planning, but at the moment, there’s no evidence anywhere in the world AstraZeneca effectiveness against severe infection is affected by any of these variants of concern.

And that is the fact. What we have at the moment is a small group of people in a study not yet peer-reviewed or published in South Africa where there was an effect on the mild or moderate disease in relation to that variant of concern in that country. But there were no severe infections in any of the people that received the vaccine in regards to any of those types of the virus.”